^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    B2M-HLA-E fusion

    i
    Other names: B2M, Beta-2-microglobulin, HLA-E, Major Histocompatibility Complex, Class I, E, HLA Class I Histocompatibility Antigen, Alpha Chain E, MHC Class I Antigen E, HLA-6.2, MHC Class Ib Antigen, HLAE, QA1
    Entrez ID:
    567; 3133
    Related biomarkers:
    Expression
    Mutation
    Others
    1year
    CLL-1-Targeted Allogeneic CAR-T Cells Exhibit High on-Target Specificity and Potent Cytotoxicity in Preclinical Models of Acute Myeloid Leukemia (ASH 2023)
    CB-012 demonstrated highly specific and potent CLL-1-targeted cytolytic activity in vitro and in vivo. Specificity of the anti-CLL-1 scFv was further demonstrated by screening in an unbiased protein-binding study and no adverse safety signals were observed in murine models. These data support advancing the development of CB-012 into a first-in-human clinical trial for patients with r/r AML.
    Preclinical • CAR T-Cell Therapy • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • B2M (Beta-2-microglobulin) • HLA-E (Major Histocompatibility Complex, Class I, E)
    |
    PD-L1 expression • B2M elevation • B2M-HLA-E fusion
    |
    CB-012
    almost2years
    CB-012, an allogeneic anti-CLL-1 CAR-T cell therapy engineered with next-generation CRISPR technology to resist both the immunosuppressive tumor microenvironment and immune cell-mediated rejection, for patients with relapsed or refractory acute myeloid leukemia (AACR 2023)
    CLL-1 is a compelling therapeutic target as it is highly expressed on AML tumor cells and leukemic stem cells, but not expressed on hematopoietic stem cells. It has also been established as a target in human proof-of-concept studies. CB-012 demonstrated potent and specific CLL-1-targeted cytolytic activity, and the genome-editing strategy employed to manufacture and armor CB-012 conferred a functional advantage in the context of the potentially immunosuppressive tumor microenvironment associated with r/r AML.
    Clinical • CAR T-Cell Therapy • PD(L)-1 Biomarker • IO biomarker • Immune cell
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • B2M (Beta-2-microglobulin) • HLA-E (Major Histocompatibility Complex, Class I, E)
    |
    PD-L1 expression • B2M elevation • B2M-HLA-E fusion
    |
    CB-012